OncoSec Announces Closing of First Tranche of $15 Million At Market Investment from Alpha Holdings, Inc.
Published: Oct 09, 2018
SAN DIEGO and PENNINGTON, N.J., Oct. 9, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced the closing of the first $8 million tranche of its $15 million investment from Alpha Holdings, Inc. (KOSDAQ: 117670). This value-focused, fundamental strategic investment is centered on the clinical development of OncoSec's lead immunotherapy product candidate, TAVO (tavokinogene telseplasmid). TAVO enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with powerful immune-stimulating functions.
Alpha Holdings is a leading Korean technology company engaged in the design, development, service and manufacture of system semiconductors, as well as the development of biotechnologies and thermal compound materials. Since 2002, Alpha Holdings has successfully carried out many projects as a major partner of Samsung Advanced Foundry Eco-system (SAFE) of Samsung Electronics. Alpha Holdings, a listed company in the KOSDAQ Market, was founded in 2002 and is headquartered in Seongnam, South Korea.
Under the terms of the agreement, Alpha Holdings has committed to purchase a total of $15 million worth of shares of common stock from OncoSec in two tranches at $1.50 per share. The two tranches are each subject to a six-month holding requirement from date of funding. As stated above, Alpha has funded the first tranche of $8 million. The closing of the second tranche is subject to the satisfaction of certain closing conditions. Further details of the transaction can be found in the Form 8-K filed by the Company describing the agreement.
About Alpha Holdings, Inc.
About OncoSec Immunotherapies
View original content to download multimedia:http://www.prnewswire.com/news-releases/oncosec-announces-closing-of-first-tranche-of-15-million-at-market-investment-from-alpha-holdings-inc-300727682.html
SOURCE OncoSec Medical Incorporated
Company Codes: NASDAQ-SMALL:ONCS, Korea:117670